Fuse Science, Inc. and Macular Health Advance Commercial Development of AREDS2 Drop Formulation

MIAMI LAKES, Fla., May 23, 2013

"We have been anxiously awaiting the results of the AREDS2 study, so that we could incorporate the findings into the new Macular Health Drop Formulation.  The ideal Drop formulation is well underway and we expect to begin clinical testing in July," said Macular Health's Chief Executive officer, Jeffery McAnnally.  "We believe this study paves the way for an even bigger relationship between Macular Health and Fuse Science."

In 2001, researchers with the Age-Related Eye Disease Study ("AREDS") reported that an AREDS formulation reduced the risk of developing advanced age-related macular degeneration by 25% over a five year period of time.  In 2006, the same research group began a study called AREDS2 to determine if they could improve the formulation.  In AREDS2, subjects took one of four formulations daily for a five year period of time. The AREDS2 study results provided new information on preventing vision loss and determined which ingredients are vital to minimizing potential adverse events.  While there is no cure for AMD, Macular Health, by implementing Fuse Science's Drop delivery technology in its formulation, believes that it can help AMD sufferers slow the progression of vision loss, which is the leading cause of blindness in adults in the United States. 

"We are extremely excited to provide our proprietary Drop delivery technology for the development of the new AREDS2 Macular Health Drop formulation," said Jeanne Hebert, Fuse Science's Vice President of Marketing & Clinical Research. "We believe that this new Drop formulation may potentially have life-changing results for patients with AMD.  It also may redefine a multi-million dollar product category and change how AMD sufferers receive nutritional supplements to slow the progression of Age Related Macular Degeneration."

Macular Health's McAnnally was recently interviewed by the Birmingham Business Journal with respect to the results of the study conducted by the National Eye Institute which were released on May 5, 2013 and which confirmed that Macular Health's capsule is the "ideal formulated product for combating age-related central vision loss, otherwise known as macular degeneration."  

About Age-Related Macular Degeneration
Macular degeneration is the leading cause of blindness in American adults. The condition, which is a breakdown of the macula of the eye, typically occurs during the aging process. Damage of the macula, caused by macular degeneration, increases the difficulty of seeing fine details clearly.  Macular degeneration can make activities such as reading and threading a needle impossible. The ability to see both near and far is hindered by macular degeneration because damage to the macula causes blurriness and distortion of vision. There is no cure for macular degeneration, but there is hope of slowing vision loss with proper nutrition.  For more information, visit www.macularhealth.com.

About Fuse Science, Inc.
Fuse Science, Inc. (OTCQB: DROP), is an innovative consumer products and delivery technology company based in Miami Lakes, Florida.  Fuse Science holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals.  The Company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly - all in a concentrated "DROP" form that is simply applied under the tongue.  The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products.  Information about Fuse Science is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).